Response to ASX Price Query

• Inoviq published an ASCO abstract with study results on the EXO-OC test
• Inoviq is relying on Listing Rule 3.1A to not announce the upcoming ASCO poster presentation early
• The new ASCO poster presentation data is considered price sensitive

Inoviq Ltd responded to an ASX price query, stating that it published an ASCO abstract with study results on the EXO-OC test on May 22, 2025. The company believes some shareholders may have missed or misunderstood the significance of the previous announcements, and the new information to be delivered in the ASCO poster presentation on June 1, 2025 is considered price sensitive. Inoviq is relying on Listing Rule 3.1A to not announce the ASCO poster presentation early, as the data is the subject of a draft Australian Provisional Patent Application that is not yet finalized, and the information remains a trade secret and confidential under ASCO's strict embargo policy. Inoviq confirms it is complying with the Listing Rules and its continuous disclosure obligations.